Mark Kessel Partner Symphony Capital LLC June 3, 2010 Business Development Key Ingredient for Success.

Slides:



Advertisements
Similar presentations
CTI LIFE SCIENCES FUND Role of a VC in Helping Commercialize Early Stage Innovation November 19 th 2007 Presented by: Richard J. Meadows Managing Partner.
Advertisements

1 CTI Life Sciences Fund Introduction January 2008.
IAVIs Brooklyn Design Laboratory/Historic Tax Credit Transaction By Mike Goldrich Executive Vice President & COO June 24, 2009.
Process and mechanics of HFA progress monitoring and Review Sujit Mohanty, UNISDR The Hyogo Framework for Action Progress Review and Reporting.
WBB Securities, LLC © WBB Securities, LLC 2007 A Forward Looking Strategy For Biotech Businesses.
Science-Based Development A regional perspective from STCP/IITA Martine Ngobo, Stephan Weise & STCP Team Sustainable Tree Crops Program International Institute.
Digital Agenda for Europe Supporting Innovation Bror Salmelin Advisor to the DG European Commission
Developing and Executing a Global Data Strategy March 16, 2010
Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane.
UNN development The Knowledge Triangle Developing internationally competitive programs RESEARCH INNOVATION EDUCATION.
Biosciences Innovation Policy Consortium for Eastern Africa (BIPCEA) Towards a Bio-economy in Eastern Africa Julius Ecuru 29/9/11 Kampala, Uganda.
1 Winning Professional Accountant Suresh Gooneratne Diesel & Motor Engineering PLC 20 October, 2012.
Source: Financial Times of London Global Banks 1999 – 2009 “Changing of the Guard”
Frank van Harmelen Vrije Universiteit Amsterdam The Web of data and LarKC’s role in it Creative Commons License: allowed to share & remix, but must attribute.
Name ____________________ Date ___________ Period ____.
Global Demand Driven Research- system solutions Östen Ekengren IVL-Swedish Environmental Research Institute Stockholm Cleantech EUCETSA.
2nd Panel, Best Practices: “ IPR in Successful University-Industry Collaborations” Dr. Tamar Raz, CEO Hadasit, the Technology Transfer Company of Hadassah.
Dec.11, 2008 Raymond James Boston Fall Investors Conference Boston, Massachusetts.
CIPLA LTD Analyst Report By Siddharth Ghaisas. WHO IS CIPLA & WHAT DO THEY DO? WHO WHO - The Chemical, Industrial & Pharmaceutical Laboratories; - Founded.
Brand Protection: In the face of mounting counterfeiting, diversion & other infringements Jim Mentone | Director, Consumer Global Brand Protection.
Miles Eddowes Open Innovation Champion Kraft Foods October 22, 2010 OPEN INNOVATION CASE STUDIES.
1 EMERGING ENERGY & ENVIRONMENT, LLC TOWARDS A LOW CARBON ECONOMY: THE ROLE OF PRIVATE EQUITY FUNDS BY: JOHN PAUL MOSCARELLA Emerging Energy & Environment,
1 Chapter 12 Strategic Entrepreneurship PART IV MONITORING AND CREATING ENTREPRENEURIAL OPPORTUNITIES.
EXPANSION STRATEGIES OF AN ENTERPRISE AUTHOR: ALPANA TREHAN CHAPTER-5 © 2011, Dreamtech Press :: Chapter 5 1.
The Miracle of Science. DuPont was founded in 1802 Second largest chemical company Net profit Operates in 70 countries Headquartered Employs Market-Driven.
Innovation and Efficiency in clinical research solutions Clinical Trial solutions Luca Emili – CEO
Strengths and Gaps in the Canadian Vaccine Landscape: a biotech perspective Nathalie Charland, PhD Sr. Director, Scientific liaisons Vaccine Innovation.
Confidential | © 2013 Third Rock Ventures Building Biotechnology Companies from Scratch: Strategy and Approaches Robert I. Tepper, MD PAGE1.
M&A STRATEGY One of most fundamental motives for M&A is growth. Companies seeking to expand are faced with a choice between internal or organic growth.
DAVID HARDING CPhI 2008 SHANGHAI JUNE 24–26, 2008 Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Partnerships & Alliances Molecular Diagnostics Prof. K. K. Jain MD, FRACS, FFPM CEO, Jain PharmaBiotech Blaesiring 7, 4057 Basel, Switzerland Colloquim.
Global Market Entry Strategies
PHRM 8660 PHARMACEUTICAL MARKETING RIAN MARIE EXTAVOUR; APRIL 11 TH 2013 TRACKING PROJECT: IMS HEALTH.
Ohio Venture Association The Quiet Recovery – the Regional Core Competencies of Our Expanding Venture Community September 12, 2008 Mark G. Heesen President.
Introduction Capgemini is headquartered in Paris, France and operates in more than 40 countries Around 120,000 people in North and South America, Europe.
Investing in the State of Innovation International Seminar on Knowledge and Innovation 1 October, 2013 Creating a High-Performance Innovation Ecosystem:
# MCL 0 Today’s Venture Capital Environment Ted R. Woolschlager Director, Emerging Growth Markets Mid-Atlantic Area Ernst & Young June.
The State of the Massachusetts Life Science Industry - The Year in Review - June 2, 2011 MALSI | MA Life Sciences Innovation Day.
VED S.A.. VED Your trusted partner for Investment Management, Mergers & Acquisitions and Real Estate Investments VED S.A. 1.
MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.
The Business Model Canvas The Building Blocks for a Successful Business PCBN Pacific Coast Business Networking June 10, 2015.
1 McMaster Presentation June 20, 2002 Shameze Rampertab.
Outsourcing in UNILEVER
Protection of Intellectual Property in Canada George Jackowski, Ph.D., KCTJ October 19 th, 2015 Chairman of NAVA Corp.
Cegedim Relationship Management Key Perspectives on Customer Databases November 2013.
1 Samer AlAshgar January 9 th, 2016 Status and prospects for Energy Research in the MENA region.
Mark Swinchatt Regional Business Director – Asia Pacific AUSVEG Conference April 2011.
FEBRUARY 25, 2014 © Emergence Confidential SEAN JACOBSOHN | VENTURE
Best Practices for a Full Value Chain Approach Open Innovation Matthew C. Heim, Ph.D. President, NineSigma Inc.
© 2012 IP Technology Exchange, Inc.1 What does a small/medium Pharma-Biotech need to do to get on “Big Pharma’s” radar? Mark McBride Managing Director,
Cisco Systems Amy Kwan Annual Revenue: US $40 Billion Worldwide Presence: Culture: Innovation, Quality, Teamwork Changing the way we work, play and learn.
Agilent Technologies Discovery Begins with Measurement January 8,
Regulatory Writing and Publishing Leads Global Regulatory Outsourcing Market – Trends and Forecast
1 Dr Neil Murray BioInfect th November 2013.
Success Stories of Globalization in Korean Pharma
Design Organizations for the International Environment
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Bioreactor Market to surpass.
Gestora brasileiro focada exclusivamente na área da saúde.
Ahlstrom Big difference. Small fibers.
Finland, a Global Testbed for Personalized Cancer Research?
What Makes a Novel Technology Innovative?
GLOBAL MARKET ENTRY STRATEGIES Chapter Nine
Advanced Biofuels Leadership Conference
Ipsen Ethics & Compliance - Confidential - Only for internal use
MAZARS’ CONSULTING PRACTICE
Design Organizations for the International Environment
Proactive One2One Healthcare Forum July 11th 2019
Alza & Ciba-Geigy: Making relationships work
Presentation transcript:

Mark Kessel Partner Symphony Capital LLC June 3, 2010 Business Development Key Ingredient for Success

- 1 - Importance of Clinically Meaningful Innovation By 2020, Pay-for-Performance Will be the Norm in Many Countries Source: PricewaterhouseCoopers Pharma 2020

- 2 - Shifting Regional Biopharmaceutical Sales The Global Pharmaceutical Market by Region, 2008 & 2020 Source: PricewaterhouseCoopers Pharma 2020

- 3 - Growth of Development Programs Worldwide Source: PhRMA Pharmaceutical Profile, 2009 Number of Compounds in Development by Region

- 4 - More Unpartnered Products to Choose From Number of Unpartnered Products By Phase2007 vs Source: Oliver Wyman analysis; Goldman Sachs

- 5 - Acquisitions for Growth Number of Announced Transactions by Year: 2005 – 1H:2009 Source: Recap by Deloitte

- 6 - Acquisitions for Growth (continued) Large Pharma M&A: 2007 – 2009YTD $ Billions Number of Acquisitions Source: Business Insights Ltd., The Evolving Pharma M&A Landscape (2009)

- 7 - In-Licensing for Growth Top Licensees: 2005 – Q3:2009 Source: Recap by Deloitte

- 8 - In-Licensing for Growth (continued) Source: Recap by Deloitte 1,419 Alliances from 2005 – Q3:2009

- 9 - Approaches to Address Key Challenges Accessing cutting edge science from academic institutions Accessing early programs through venture capital arms Accessing platforms and enabling technologies Licensing pre-clinical and clinical programs Accelerating pipeline development Acquiring revenues and pipeline P&L enhancement strategies Out license compounds for developing markets Acquire compounds for Europe and developing markets Combining development and commercial efforts Avoiding over-paying by using earn out acquisitions Partnering pre-partnered drugs with Large Pharma not an impediment Hostile takeovers

Becoming the Partner of Choice: An Outsiders View Combine the best of biotech with Large Pharmas attributes Clear mandate from the top to become the partner of choice Ability to move quickly Creative approach to deal making Avoid risk avoidance Candor in dealing with collaborators Create win/win deals True collaboration and not big gorilla in the room environment Consider creative models to enhance success rate

THANK YOU